164 related articles for article (PubMed ID: 35244678)
21. Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis.
Hao J; Yu H; Zhang T; An R; Xue Y
Ther Adv Med Oncol; 2020; 12():1758835920967241. PubMed ID: 33193829
[TBL] [Abstract][Full Text] [Related]
22. Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer.
Dai D; Liu L; Huang H; Chen S; Chen B; Cao J; Luo X; Wang F; Luo R; Liu J
Front Oncol; 2021; 11():590414. PubMed ID: 33718143
[TBL] [Abstract][Full Text] [Related]
23. CD8, FoxP3, and CD45RO+ Lymphocytic Infiltrates in Type I and Type II Endometrial Cancers in African American and European American Females.
Rashid T; Young-Pierce JL; Garrett-Mayer E; Graybill W; Neal S; Spruill LS
Int J Gynecol Pathol; 2017 Nov; 36(6):540-549. PubMed ID: 28114190
[TBL] [Abstract][Full Text] [Related]
24. Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients.
Paijens ST; Vledder A; Loiero D; Duiker EW; Bart J; Hendriks AM; Jalving M; Workel HH; Hollema H; Werner N; Plat A; Wisman GBA; Yigit R; Arts H; Kruse AJ; de Lange NM; Koelzer VH; de Bruyn M; Nijman HW
Oncoimmunology; 2021 Jun; 10(1):1935104. PubMed ID: 34123576
[TBL] [Abstract][Full Text] [Related]
25. Profiling the immune landscape in mucinous ovarian carcinoma.
Meagher NS; Hamilton P; Milne K; Thornton S; Harris B; Weir A; Alsop J; Bisinoto C; Brenton JD; Brooks-Wilson A; Chiu DS; Cushing-Haugen KL; Fereday S; Garsed DW; Gayther SA; Gentry-Maharaj A; Gilks B; Jimenez-Linan M; Kennedy CJ; Le ND; Piskorz AM; Riggan MJ; Shah M; Singh N; Talhouk A; Widschwendter M; Bowtell DDL; Candido Dos Reis FJ; Cook LS; Fortner RT; García MJ; Harris HR; Huntsman DG; Karnezis AN; Köbel M; Menon U; Pharoah PDP; Doherty JA; Anglesio MS; Pike MC; Pearce CL; Friedlander ML; DeFazio A; Nelson BH; Ramus SJ
Gynecol Oncol; 2023 Jan; 168():23-31. PubMed ID: 36368129
[TBL] [Abstract][Full Text] [Related]
26. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
Li J; Wang J; Chen R; Bai Y; Lu X
Oncotarget; 2017 Feb; 8(9):15621-15631. PubMed ID: 28152503
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer.
Shah CA; Allison KH; Garcia RL; Gray HJ; Goff BA; Swisher EM
Gynecol Oncol; 2008 May; 109(2):215-9. PubMed ID: 18314181
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
30. Survival disparities among racial/ethnic groups of women with ovarian cancer: An update on data from the Surveillance, Epidemiology and End Results (SEER) registry.
Stenzel AE; Buas MF; Moysich KB
Cancer Epidemiol; 2019 Oct; 62():101580. PubMed ID: 31400533
[TBL] [Abstract][Full Text] [Related]
31. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
[TBL] [Abstract][Full Text] [Related]
32. Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers.
Kim KJ; Lee KS; Cho HJ; Kim YH; Yang HK; Kim WH; Kang GH
Hum Pathol; 2014 Feb; 45(2):285-93. PubMed ID: 24331841
[TBL] [Abstract][Full Text] [Related]
33. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
[TBL] [Abstract][Full Text] [Related]
34. Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer.
Gallego A; Mendiola M; Hernando B; Berjon A; Cadiz A; Chaves-Urbano B; Heredia-Soto V; Spagnolo E; Hernández Gutiérrez A; Hardisson D; Macintyre G; Redondo A; Garcia MJ
Int J Gynecol Cancer; 2022 Aug; 32(8):1009-1016. PubMed ID: 35437272
[TBL] [Abstract][Full Text] [Related]
35. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.
Leonard B; Starrett GJ; Maurer MJ; Oberg AL; Van Bockstal M; Van Dorpe J; De Wever O; Helleman J; Sieuwerts AM; Berns EM; Martens JW; Anderson BD; Brown WL; Kalli KR; Kaufmann SH; Harris RS
Clin Cancer Res; 2016 Sep; 22(18):4746-55. PubMed ID: 27016308
[TBL] [Abstract][Full Text] [Related]
36. Black and Hispanic women are less likely than white women to receive guideline-concordant endometrial cancer treatment.
Kaspers M; Llamocca E; Quick A; Dholakia J; Salani R; Felix AS
Am J Obstet Gynecol; 2020 Sep; 223(3):398.e1-398.e18. PubMed ID: 32142825
[TBL] [Abstract][Full Text] [Related]
37. Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma.
Hagemann AR; Hagemann IS; Cadungog M; Hwang WT; Patel P; Lal P; Hammond R; Gimotty PA; Chu CS; Rubin SC; Birrer MJ; Powell DJ; Feldman MD; Coukos G
Cancer Biol Ther; 2011 Aug; 12(4):367-77. PubMed ID: 21785280
[TBL] [Abstract][Full Text] [Related]
38. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
[TBL] [Abstract][Full Text] [Related]
39. Racial differences in CD8
Abdou Y; Attwood K; Cheng TD; Yao S; Bandera EV; Zirpoli GR; Ondracek RP; Stein L; Bshara W; Khoury T; Ambrosone CB; Omilian AR
Breast Cancer Res; 2020 Jun; 22(1):62. PubMed ID: 32517730
[TBL] [Abstract][Full Text] [Related]
40. Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial).
Googe PB; Theocharis S; Pergaris A; Li H; Yan Y; McKenna EF; Moschos SJ
Curr Probl Cancer; 2022 Jun; 46(3):100862. PubMed ID: 35398635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
